1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Idarubicin Hydrochloride Powder for Injection

Trade Name: IDAMYCIN; ZAVEDOS
Chemical Family: Mixture
Intended Use: Pharmaceutical product used as Antineoplastic

2. HAZARDS IDENTIFICATION

Appearance: Red-orange lyophilised cake
Signal Word: DANGER

Statement of Hazard:
Fatal if swallowed.
May damage fertility or the unborn child.
Suspected of damaging fertility or the unborn child.
Suspected of causing genetic defects.
Suspected of causing cancer.

Additional Hazard Information:
Short Term: May cause skin irritation. (based on animal data).
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on blood and blood forming organs, gastrointestinal system, lymphatic system, male reproductive system, liver, kidneys, heart, and developing fetus. Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions.

Known Clinical Effects:
Bone marrow suppression is the most serious adverse effect seen during clinical use. Adverse effects associated with the therapeutic use include effects on cardiovascular system, gastrointestinal system, liver, kidney, and skin rash. Cardiac toxicity. Drugs of this class have been associated with rare, but potentially serious cardiac events. These events have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at increased risk from exposure.

EU Indication of danger:
Very toxic
Toxic to reproduction: Category 1
Carcinogenic: Category 3
Mutagenic: Category 3

EU Hazard Symbols:
2. HAZARDS IDENTIFICATION

EU Risk Phrases:
- R28 - Very toxic if swallowed.
- R40 - Limited evidence of a carcinogenic effect
- R60 - May impair fertility.
- R61 - May cause harm to the unborn child.
- R68 - Possible risk of irreversible effects.

Australian Hazard Classification (NOHSC):

Note:
This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Idarubicin Hydrochloride</td>
<td>57852-57-0</td>
<td>260-990-7</td>
<td>T+;R28</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Repr.Cat.2;R60</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Repr.Cat.2;R61</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Carc.Cat.3;R40</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mut.Cat.3;R68</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactose NF, anhydrous</td>
<td>63-42-3</td>
<td>200-559-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:
* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire. May include oxides of carbon. May include oxides of nitrogen. May include hydrogen chloride.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Prevent exposure by any route. Personnel must wear appropriate protective equipment (see Section 8).

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release. Prevent product from entering drains.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Restrict access to work area. Minimize dust generation and accumulation. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. It is recommended that all operations be fully enclosed and no air recirculated.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Idarubicin Hydrochloride

Pfizer OEL TWA-8 Hr: 0.1µg/m³

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

- **Hands:** Impervious, disposable gloves (double suggested) are recommended if skin contact with drug product is possible and for bulk processing operations.
- **Eyes:** Wear safety glasses or goggles if eye contact is possible.
- **Skin:** Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
- **Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

### 9. PHYSICAL AND CHEMICAL PROPERTIES:

- **Physical State:** Freeze-dried preparation
- **Color:** Red-orange
- **Molecular Formula:** Mixture
- **Molecular Weight:** Mixture

### 10. STABILITY AND REACTIVITY

- **Stability:** Stable under normal conditions of use.
- **Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.
- **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers.
**11. TOXICOLOGICAL INFORMATION**

**General Information:** The information included in this section describes the potential hazards of the active ingredient.

**Acute Toxicity: (Species, Route, End Point, Dose)**

<table>
<thead>
<tr>
<th>Species</th>
<th>Route</th>
<th>End Point</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Oral</td>
<td>LD50</td>
<td>5.43 mg/kg</td>
</tr>
<tr>
<td>Mouse</td>
<td>Oral</td>
<td>LD50</td>
<td>13.98 mg/kg</td>
</tr>
<tr>
<td>Rat</td>
<td>Intravenous</td>
<td>LD50</td>
<td>3.08 mg/kg</td>
</tr>
<tr>
<td>Mouse</td>
<td>Intravenous</td>
<td>LD50</td>
<td>4.10 mg/kg</td>
</tr>
</tbody>
</table>

**Acute Toxicity Comments:** A greater than symbol (>), indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

**Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)**

<table>
<thead>
<tr>
<th>Duration</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>End Point</th>
<th>Target Organ</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Month(s)</td>
<td>Dog</td>
<td>Oral</td>
<td>0.08 mg/kg/day</td>
<td>NOAEL</td>
<td>Blood forming organs, Immune system, Lymphatic system, Gastrointestinal System, Liver, Male reproductive system</td>
</tr>
<tr>
<td>13 Week(s)</td>
<td>Rat</td>
<td>Oral</td>
<td>0.192 mg/kg/day</td>
<td>NOAEL</td>
<td>Blood forming organs, Immune system, Lymphatic system, Kidney, Heart, Liver, Gastrointestinal system</td>
</tr>
<tr>
<td>13 Week(s)</td>
<td>Dog</td>
<td>Oral</td>
<td>0.15 mg/kg/day</td>
<td>NOAEL</td>
<td>Blood forming organs, Immune system, Lymphatic system, Gastrointestinal system, Liver</td>
</tr>
<tr>
<td>13 Week(s)</td>
<td>Rat</td>
<td>Intravenous</td>
<td>0.064 mg/kg/day</td>
<td>NOAEL</td>
<td>Blood forming organs, Immune system, Lymphatic system, Gastrointestinal system, Kidney, Heart</td>
</tr>
<tr>
<td>13 Week(s)</td>
<td>Dog</td>
<td>Intravenous</td>
<td>0.045 mg/kg/day</td>
<td>NOAEL</td>
<td>Blood forming organs, Immune system, Lymphatic system, Gastrointestinal system</td>
</tr>
</tbody>
</table>

**Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))**

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>End Point</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Embryo / Fetal Development</td>
<td>Rat</td>
<td>Intravenous</td>
<td>0.195 mg/kg/day</td>
<td>LOAEL</td>
<td>Embryotoxicity, Teratogenic, Fetotoxicity</td>
</tr>
<tr>
<td>Embryo / Fetal Development</td>
<td>Rabbit</td>
<td>Intravenous</td>
<td>0.203 mg/kg/day</td>
<td>LOAEL</td>
<td>Not Teratogenic, Embryotoxicity, Maternal Toxicity</td>
</tr>
<tr>
<td>Fertility and Embryonic Development</td>
<td>Rat</td>
<td>Intravenous</td>
<td>0.01 mg/kg/day</td>
<td>NOAEL</td>
<td>Maternal Toxicity, Paternal toxicity, Fetotoxicity</td>
</tr>
</tbody>
</table>

**Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Cell Type/Organism</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial Mutagenicity (Ames)</td>
<td><em>Salmonella</em></td>
<td>Positive</td>
</tr>
<tr>
<td>Mitotic Gene Conversion</td>
<td>Not specified</td>
<td>Positive</td>
</tr>
<tr>
<td><em>In Vitro</em> Mammalian Cell Mutagenicity</td>
<td>Hamster</td>
<td>Positive</td>
</tr>
<tr>
<td><em>In Vitro</em> Chromosome Aberration</td>
<td>Human Lymphocytes</td>
<td>Positive</td>
</tr>
</tbody>
</table>

**Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

<table>
<thead>
<tr>
<th>Duration</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>End Point</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 Week(s)</td>
<td>Rat</td>
<td>Intravenous</td>
<td>0.06 mg/kg/month</td>
<td>LOAEL</td>
<td>Benign tumors, Malignant tumors</td>
</tr>
</tbody>
</table>

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.
12. ECOLOGICAL INFORMATION

Environmental Overview:
The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures:
Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
### 15. REGULATORY INFORMATION

**EU Symbol:** T+
**EU Indication of danger:**
- Very toxic
- Toxic to reproduction: Category 1
- Carcinogenic: Category 3
- Mutagenic: Category 3

**EU Risk Phrases:**
- R28 - Very toxic if swallowed.
- R40 - Limited evidence of a carcinogenic effect
- R60 - May impair fertility.
- R61 - May cause harm to the unborn child.
- R68 - Possible risk of irreversible effects.

**EU Safety Phrases:**
- S22 - Do not breathe dust.
- S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.
- S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
- S53 - Avoid exposure - obtain special instructions before use.

**OSHA Label:**
- DANGER
- Fatal if swallowed.
- May damage fertility or the unborn child.
- Suspected of damaging fertility or the unborn child.
- Suspected of causing genetic defects.
- Suspected of causing cancer.

**Canada - WHMIS: Classifications**

**WHMIS hazard class:**
- Class D, Division 1, Subdivision A
- Class D, Division 2, Subdivision A

**Idarubicin Hydrochloride**

- California Proposition 65: male reproductive toxicity, initial date 8/20/99
devotional toxicity, initial date 8/20/99

**EU EINECS/ELINCS List**

- 260-990-7

**Lactose NF, anhydrous**

- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 200-559-2
16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R28 - Very toxic if swallowed.
R40 - Limited evidence of a carcinogenic effect
R60 - May impair fertility.
R61 - May cause harm to the unborn child.
R68 - Possible risks of irreversible effects.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 5 - Fire Fighting Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations. Updated Section 14 - Transport Information. Updated Section 15 - Regulatory Information.

Prepared by: Corporate Occupational Toxicology & Hazard Assessment

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet